All In Biotech

Drug Trial Radar · NCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

316

Planned (sponsor's estimate)

Start

Aug 6, 2021

Primary completion

Jun 30, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Simcha IL-18, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.

Conditions

  • Cancer
  • Solid Tumor
  • Melanoma
  • Renal Cell Carcinoma
  • Triple-negative Breast Cancer
  • Non Small Cell Lung Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Carcinoma
  • MSI-High

Interventions

  • ST-067Biological

    ST-067 is an engineered variant of human interleukin-18.

  • Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]Biological

    Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.

  • pembrolizumabBiological

    Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the maximum tolerated dose of ST-067 in phase 1a monotherapyTime frame: Day 29
  2. Evaluate the overall safety and tolerability of ST-067 in combination with pembrolizumabTime frame: Day 29
  3. Number of Participants With Treatment-Related Adverse EventsTime frame: Day 29
  4. Initial assessment of efficacy in phase 2Time frame: At 8 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.